The 2024 “8th Future Healthcare Ecosystem Expo” (hereinafter referred to as “VBEF”) has officially concluded. Themed “New Youth,” this year’s VBEF was organized by VCBeat, VB100, VCBeat Research Institute, and Artery Orange, with strategic cooperation and support from the Administrative Committee of Tianjin Binhai Zhongguancun Science Park and Beitang Bay Digital Economy Industrial Park. The Future Healthcare Ecosystem Exhibition Area was jointly presented in collaboration with Health Intelligence Valley.Over 10,000 participants attended the conference throughout its duration., including national academicians, experts and scholars, corporate founders, institutional partners, local investment promotion representatives, channel distributors, and “overseas buyer delegations,” are widely present at major events such as trend summits, product launches, niche-sector forums, project roadshows, exhibition booths, and matchmaking sessions.

This edition of VBEF features five major exhibition zones, attracting over 3,000 participating enterprises and more than 500 global investment buyer delegations, while inviting over 500 industry leaders to share the latest insights. On the first day of the expo, four key topics—latest advancements in the translation of scientific research achievements, development of local medical industry ecosystems, the wave of global expansion, and innovative development of medical services—garnered particular attention, becoming focal points for attendees andThe areas of greatest concern to industry professionals attending the exhibition are likely to become important trends in the development of the healthcare industry in the coming period.

During the exhibition, our booth attracted a large influx of visitors.Yikexin ProductsAttracting numerous attendees to stop and inquire, Yikexin staff provided comprehensive explanations to each guest, coveringFeaturing Bior-econcile™ Anminxin®’s exclusive soothing patented technology, human efficacy trials conducted by authoritative institutions, cell-level scientific research, and the Nine-Dimensional Golden Shield comprehensive testing by authoritative institutions,Fully demonstrating Yikexin’s specialized research in skincare solutions for specific skin concerns, it garnered widespread attention and recognition from attendees.
“Our account managers responsible for exhibiting companies reported that nearly 100 visitors added us on WeChat at our booth over the past few days. There was strong interest in our products, and many professional attendees expressed their intention to visit our company for further discussions. We estimate there are more than 20 potential clients with serious interest.”

During the exhibition, Beijing Zhongyan Chuangke Medical Technology Co., Ltd. achieved a total score of 6,655 points,Topped the Popularity Exhibitor Awards!It fully showcased our company’s professional image at the trade show, attracting widespread attention from attendees.

This exhibition provided Yikexin with a valuable opportunity to not only strengthen ties with both new and existing clients, but also fully demonstrate its efficacy and strength in the field of dermatological medicine. Moving forward, Yikexin will continue to uphold its customer-centric service philosophy, drive continuous innovation, and remain committed to delivering high-quality, high-efficacy, and high-tech products and services, thereby contributing greater momentum to the industry’s development.

About Yikexin
Yikexin was developed by a research and development team led by dermatology experts with over 30 years of frontline clinical experience, along with pharmaceutical experts and formulation engineers. Using immune-mediated inflammatory skin conditions as the research model and leveraging its exclusive soothing patent, Yikexin has created skincare solutions for autoimmune diseases, chronic conditions, and special populations. By targeting effector cells, it introduces functional skincare products suitable for long-term patient use. The overall brand architecture of Yikexin primarily focuses on managing three major categories of skin issues: systemic chronic diseases, special populations including the elderly and neonates, and adverse reactions following tumor radiotherapy and chemotherapy. Skincare products for chronic wounds and related long-term management studies are currently underway. Furthermore, Zhongyan Chuangke will continue to expand multidisciplinary applied research and outcome incubation, further accelerating the translation of scientific achievements in the field of dermatology.